ライフサイエンスコーパス: PDT

1 PDT (660-nm light) was carried out against S. mutans bio

2 PDT was achieved with Ag NRs using low irradiation (1.4

3 PDT was applied with verteporfin at a dose of 6 mg/m(2)

4 PDT-treated patients in the focal and diffuse leakage gr

5 A total of 116 PDT sessions were performed (mean, 1.5 sessions; range,

6 erapy vs. 5.6 combination therapy; mean, 1.2 PDT sessions), respectively.

7 gon laser photocoagulation (42.1% vs. 0.4%), PDT (0% vs. 43.8%), transpupillary thermotherapy (0% vs.

8 acuity of 20/400 (pre-PDT era) versus 20/63 (PDT era).

9 conjugated photosensitizers, resulting in a PDT effect.

10 lexes utilize blue or UV-A light to obtain a PDT effect, limiting the penetration depth inside tissue

11 d cycle of curettage and aminolevulinic acid PDT with resolution.

12 ed curettage followed by aminolevulinic acid PDT.

13 of a targeted PDT agent for IGS and adjuvant PDT.

14 After PDT for chronic CSCR we observed sustained reductions in

15 ment in BCVA at months 1, 3, 6, and 12 after PDT (P < .05 for all times).

16 ediate to poor visual acuity (<=20/50) after PDT.

17 umor xenografts immediately before and after PDT at different time points.

18 omography (OCT), and recurrence of CSC after PDT were compared between the 2 groups.

19 At 36 months after PDT, 132 eyes (97.1%) achieved complete resolution of SR

20 d recurrence rate of CSCR at 36 months after PDT.

21 Recurrences after PDT tend to occur along the tumor edges, often with mini

22 In this comparative analysis, PDT was an effective treatment method for circumscribed

23 In conclusion, both CBT and PDT appear to potentially offer some benefit for FND, al

24 , function and resource use for both CBT and PDT.

25 Dual-mode imaging and PDT was subsequently performed in tumor-bearing mice.

26 Measuring and monitoring intrinsic and PDT-induced tumor hypoxia in vivo during PDT is of high

27 o overcome some of the limitations of RT and PDT in cancer treatment.

28 both the advantages of radiotherapy (RT) and PDT, and has considerable potential applications in clin

29 intained follow-up (40 eyes, 45 tumors), and PDT achieved tumor control with 1 session (n = 32 tumors

30 es had complete SRF resolution after another PDT treatment.

31 es iridium corroles particularly exciting as PDT drug candidates.

32 Both MN-assisted PDT and PTT are light-mediated phototherapy methods and

33 MN-assisted PDT or PTT has been studied for various applications by

34 ng recent developments of nanoparticle-based PDT agents, their combinations with different drugs, des

35 uding subretinal fluid, were recorded before PDT and during follow-up examinations.

36 e, lack of CME, and lack of treatment before PDT.

37 D viability imaging revealed synergy between PDT and the standard-of-care chemotherapeutic carboplati

38 hese data point to a novel "thiol-blocked" [(PDT)Mo(V)O(S(Cys))(thiolate)](-) structure, which is sup

39 s have emerged as promising systems for both PDT and PCT.

40 a intra-tumoral injection could prolong both PDT agents retention in tumor.

41 review summarizes the challenges to bringing PDT into mainstream cancer therapy.

42 llular targeted-PDT, 48 h), or both V- and C-PDT (9 h).

43 ieve V-PDT (vascular targeted-PDT, 0.5 h), C-PDT (cellular targeted-PDT, 48 h), or both V- and C-PDT

44 a promising nanoplatform for enhanced cancer PDT.

45 ly viewed as the starting point for clinical PDT in modern medicine.

46 ic index and extend the spectrum of clinical PDT far beyond what was imagined when that sentinel manu

47 describe a treatment strategy that combines PDT by a new chlorin-based nanoscale metal-organic frame

48 mor-centered approach, as part of a complete PDT package that includes the light component and the pr

49 Case-control review of 38 consecutive PDT-naive macular PCV patients who underwent verteporfin

50 ison of clinical features for tumor control (PDT alone vs. PDT plus additional therapy) revealed thos

51 ting energy transfer-based (1) O2 controlled PDT.

52 l, which is not possible for the counterpart PDT nanoagent.

53 g and (2) Cherenkov-photodynamic therapy (CR-PDT) on cells could be achieved under conditions mimicki

54 The ISC process is turned off to deactivate PDT ability, when the PS is transferred or metabolized a

55 ry/release, near-infrared (NIR)-excited deep PDT, and radiosensitization, respectively, all of which

56 ted the therapeutic success of the delivered PDT.

57 ted against several dermatological diseases (PDT) and (antibiotic-resistant) pathogenic microorganism

58 Crossover to half-dose PDT after previous unsuccessful HSML treatment for cCSC

59 ic CSCR are recommended to undergo half-dose PDT before they have significant visual deterioration.

60 ients with chronic CSCR undergoing half-dose PDT between 2005 and 2011 were reviewed.

61 Chronic CSCR patients treated with half-dose PDT can achieve long-term stable visual acuity and resol

62 nts, while crossover to HSML after half-dose PDT does not seem to significantly affect these endpoint

63 Half-dose PDT is superior to HSML treatment in cCSC patients, rega

64 Patients were treated with either half-dose PDT or HSML (both indocyanine green angiography-guided)

65 ed crossover treatment with either half-dose PDT or HSML.

66 y to develop CSCR recurrence after half-dose PDT.

67 onstrate that combination of single low-dose PDT and a subclinical dose of nanoliposomal irinotecan s

68 Standard duration PDT was used in most cases (83 seconds; n = 110/116 [95%

69 t of ALA-induced PpIX in cancer cells during PDT.

70 However, oxygen consumption during PDT can result in an inadequate oxygen supply which redu

71 aptive modification of light delivery during PDT on a fine scale to optimize treatment response.

72 and PDT-induced tumor hypoxia in vivo during PDT is of high interest for prognostic and treatment eva

73 ibits tumor growth than monotherapies (i.e., PDT or RT).

74 example of a DFT guided search for efficient PDT PSs with a substantial spectral red shift toward the

75 sitizer-MnO2 nanosystem for highly efficient PDT.

76 easing the level of GSH for highly efficient PDT.

77 cted with such helical bodipy show efficient PDT-mediated antitumor immunity amplification with an ul

78 We believe that nMOF-enabled PDT has the potential to significantly enhance checkpoin

79 oxic singlet oxygen to significantly enhance PDT.

80 lymer (POEGMA-b-P(MAA-co-VSPpaMA) to enhance PDT via the controllable release of photosensitizers.

81 ese results may indicate relatively enhanced PDT response by AFXL pretreatment in diseased skin.

82 MOF nanoparticle formulation showed enhanced PDT efficacy with superior (1) O2 control compared to th

83 However, the efficiency of existing PDT drug molecules in the deep-tissue-penetrable near-in

84 undred times lower than that of the existing PDT reagents.

85 d pain associated with microneedle expedited PDT.

86 ) of 49.5 (15.3, 7.0-66.0) months from first PDT to last follow-up.

87 treatment eye for 83 s) and reduced-fluence PDT (light dose, 25 J/cm2; dose rate, 600 mW/cm2; wavele

88 Reduced-fluence PDT was comparable to standard-fluence PDT in the treatm

89 ed with standard-fluence and reduced-fluence PDT.

90 Treatment with standard fluence PDT using verteporfin.

91 parison of outcomes between standard-fluence PDT (light dose, 50 J/cm2; dose rate, 600 mW/cm2; wavele

92 uence PDT was comparable to standard-fluence PDT in the treatment of PCV in terms of visual gains, cl

93 the efficacy of reduced and standard-fluence PDT.

94 -Cy nanoparticles may be good candidates for PDT in deeply seated tumors when combined with X-rays an

95 ntional photosensitisers used clinically for PDT are ineffective for photochemical internalisation ow

96 review summarizes recent advances in MNs for PDT or PTT.

97 ing a particular type of photoreactivity for PDT and/or PCT effects.

98 , the first Ru(II)-based photosensitizer for PDT to enter a human clinical trial.

99 performance as a triplet photosensitizer for PDT.

100 ding their potential as pH-controlled PS for PDT.

101 ays, alleviating the aerobic requirement for PDT.

102 rious microfluidic Lab-on-a-chip systems for PDT efficacy analysis on 3D culture and discusses micros

103 hat is, multimodal therapy for cancer (e.g., PDT, PTT) and antimicrobial treatment, and eventually in

104 Half-dose and half-time FA-guided PDT were both effective and safe in treating CSC and sho

105 , which ensured its effective imaging-guided PDT.

106 o address tumor hypoxia while achieving high PDT efficacy.

107 However, PDT-induced tumor hypoxia as a result of oxygen consumpt

108 n (TBP) ligands, for hypoxia-tolerant type I PDT.

109 3 transformed TiO2 from a dual type I and II PDT agent to a predominantly type I photosensitizer, irr

110 thermal effect of Au@Rh-ICG-CM also improves PDT efficacy.

111 In PDT, the effective range is limited by the distribution

112 In PDT-induced hypoxia, providing singlet oxygen from store

113 s a potential means of the (1) O2 control in PDT.

114 A statistically significant improvement in PDT mediated efficacy (p<0.001) was also observed when t

115 pite excellent healing of the oral mucosa in PDT, a lack of robust enabling technology for intraoral

116 The exploration of nMOFs in PDT, however, remains limited to an oxygen-dependent typ

117 key requirement for the generation of ROS in PDT and given the fact that hypoxia is a characteristic

118 anotechnology-based photosensitizers used in PDT.

119 market and clinical trials that are used in PDT/PDI.

120 2 ](+) or [Ru(bpy)3 ](2+) moieties to induce PDT by generating reactive oxygen species (ROS).

121 ns new avenues of particle expansion-induced PDT enhancement by controlled imidazole chemistry.

122 gy between oxaliplatin and pyrolipid-induced PDT kills tumour cells and provokes an immune response,

123 to be targeted to tumors, for X-ray-induced PDT.

124 to) aPS was also compatible to near infrared PDT with two photon excitation (800 nm) for extensive bi

125 PCV, number or type of anti-VEGF injections, PDT therapy, or baseline choroidal thickness.

126 ial and it is postulated that less intensive PDT strategies may reduce complications.

127 e some physicochemical factors that can make PDT a more viable and effective option to provide future

128 imiquimod (53.9%; 95% CI, 45.4 to 61.6), MAL-PDT (37.7%; 95% CI, 30.0 to 45.3), or ingenol mebutate (

129 yl aminolevulinate photodynamic therapy (MAL-PDT), or 0.015% ingenol mebutate gel.

130 quimod, 2.73 (95% CI, 1.87 to 3.99) with MAL-PDT, and 3.33 (95% CI, 2.29 to 4.85) with ingenol mebuta

131 RB-C(KLAKLAK)(2)-mediated PDT treatment of subcutaneous B16-F10-Luc2 tumors in C57

132 findings indicate that nanoparticle-mediated PDT can potentiate the systemic efficacy of checkpoint b

133 study than animals treated with RB-mediated PDT.

134 nerating four distinct ROSs, Ti-TBP-mediated PDT elicits superb anticancer efficacy with >98% tumor r

135 hyrin (TBP) ligands, cationic W-TBP mediates PDT to release tumor associated antigens and delivers im

136 at first evaluation and at final visit, more PDT-treated than HSML-treated patients demonstrated a re

137 at first evaluation and at final visit, more PDT-treated than HSML-treated patients showed a resoluti

138 2; dose rate, 600 mW/cm2; wavelength, 689 nm PDT applied to the treatment eye for 42 s).

139 2; dose rate, 600 mW/cm2; wavelength, 689 nm PDT applied to the treatment eye for 83 s) and reduced-f

140 There were no PDT-related complications.

141 gen greatly hinders the broad application of PDT as a first-line cancer treatment option.

142 ctors now viewed as critical determinates of PDT dose, efficacy, and toxicity, that study showed rema

143 prodrug, exhibiting the combined effects of PDT and local chemotherapy, showed better efficacy than

144 cancer cells through the combined effects of PDT and locally released PTX.

145 cancer cells through the combined effects of PDT and site-specific PTX chemotherapy.

146 However, a limitation of PDT is its dependence on light that is not highly penetr

147 tral choroid thickness (CCT), mean number of PDT treatments needed, mean number of anti-VEGF injectio

148 tumors were treated with a single session of PDT, 11 tumors received 2 sessions, 1 tumor received 3 s

149 This review describes the current status of PDT investigations using microfluidic Lab-on-a-Chip syst

150 pportunities for the clinical translation of PDT and irinotecan combination therapy for effective pan

151 a lack of high-quality controlled trials of PDT is a significant limitation, as is the lack of long-

152 ed further development and clinical usage of PDT.

153 patient and a hindrance to widespread use of PDT as standard field therapy for AK.

154 Age, gender, race, use of PDT or focal laser therapy, and central subfield thickne

155 This limits the utility of PDT in treating hypoxic tumors since lower levels of cyt

156 The optimal PDT protocol remains controversial and it is postulated

157 greatly enhanced the efficacies of RT and/or PDT.

158 mouth props that can be utilized to perform PDT in conscious subjects without the need of extensive

159 mediated by IYIY-I2-BODIPY in pre- and post-PDT conditions.

160 eyes at baseline and at 1- and 3-months post-PDT.

161 Overall, our approach potentiates PDT as a viable therapeutic option for early stage oral

162 with mean final visual acuity of 20/400 (pre-PDT era) versus 20/63 (PDT era).

163 A comparison (pre-PDT [n = 220 cases] vs. PDT [n = 238 cases]) revealed PD

164 Comparison of hemangioma managed in the pre-PDT (1967-2001) era versus PDT (2002-2018) era.

165 better visual outcome compared with the pre-PDT era, with mean final visual acuity of 20/400 (pre-PD

166 Treatment (pre-PDT vs. PDT) included argon laser photocoagulation (42.1

167 ide a new insight into the design of precise PDT.

168 bstantial risk of treatment failure, primary PDT with vertepofrin is recommended in exceptional cases

169 20 nm, 100 J/cm(2), 160 mW/cm(2)) to produce PDT effects (drug-light interval 1 h), IYIY-I2-BODIPY in

170 nsition metal complexes are highly promising PDT agents due to intense visible light absorption, yet

171 Since its publication, PDT has been increasingly utilized in clinical practice

172 use models further demonstrate that ZnP@pyro PDT treatment combined with anti-PD-L1 results in the er

173 ugs killed cancer cells surviving from rapid PDT damage via bystander effects.

174 DLI), and to investigate the impact of rapid PDT effects on the pharmacokinetic (PK) profiles of the

175 Thirty-two patients received PDT and 10 patients received HSML.

176 In eyes receiving PDT, Snellen visual acuity (VA) significantly improved a

177 w depths of tissue penetration that restrict PDT to superficial lesions, inability to treat hypoxic t

178 220 cases] vs. PDT [n = 238 cases]) revealed PDT era patients were of older mean age (48.9 vs. 53.8 y

179 ieved complete resolution of SRD with single PDT and 4 eyes (2.9%) had CSCR recurrence.

180 serous retinal detachment (SRD) with single PDT, change in best-corrected visual acuities (BCVAs), a

181 se here and demonstrate the concept of smart PDT, where pH-induced reversible twisting maximizes the

182 Specifically, PDT in conjugation with widely used chemotherapeutic dru

183 arked light source, which is unlike standard PDT, where light penetration depth is limited in biologi

184 Subsequent PDT further reduced tumor recurrence and extended animal

185 y was to determine the utility of a targeted PDT agent for IGS and adjuvant PDT.

186 ficance of this PS for mitochondria targeted PDT applications in deep tissue cancer therapy.

187 te-specific membrane antigen (PSMA)-targeted PDT agent, PSMA-1-Pc413, we showed that PSMA-1-Pc413 sel

188 rgeted-PDT, 0.5 h), C-PDT (cellular targeted-PDT, 48 h), or both V- and C-PDT (9 h).

189 prodrug to achieve V-PDT (vascular targeted-PDT, 0.5 h), C-PDT (cellular targeted-PDT, 48 h), or bot

190 nolide, 2-deoxyglucose, temsirolimus (termed PDT) regimen is a potent means of targeting AML stem cel

191 al chemotherapy, showed better efficacy than PDT alone, without systemic side effects.

192 Moreover, we show that PDT inhibited survivin expression.

193 The PDT study revealed significant cytotoxicities of porphyr

194 nd accumulating in tumors, and enhancing the PDT efficacy with a tumor growth inhibition of 96.0%.

195 After treatment, patients in the PDT era demonstrated better mean logarithm of the minimu

196 Management of choroidal hemangioma in the PDT era has allowed for significantly better visual outc

197 etinal fluid (evaluation visit: 1:48% in the PDT group and 16% in the HSML group, P = .002; final vis

198 etinal fluid (evaluation visit 1: 57% in the PDT group and 17% in the HSML group, P = .007; final vis

199 eks after treatment), 81% of patients in the PDT group had complete resolution of SRF, while none of

200 The mean retinal sensitivity in the PDT group increased from 21.7 dB (standard error [SE]: 0

201 increase in ETDRS letters was higher in the PDT-treated group when comparing baseline and first eval

202 induces tumor hypoxia, thereby weakening the PDT effect.

203 in tumor environments, improved therapeutic PDT outcomes should be achievable even under hypoxic con

204 les show superior tumor-targeted therapeutic PDT effects against cancer cells both in vitro and in vi

205 549) to test their photodynamic therapeutic (PDT) activity.

206 by aminolevulinic acid photodynamic therapy (PDT) 1 to 2 weeks later.

207 blue - MB) to mediate photodynamic therapy (PDT) against Streptococcus mutans biofilms.

208 apies: (1) verteporfin photodynamic therapy (PDT) and (2) anti-vascular endothelial growth factor (VE

209 ed to perform in vitro photodynamic therapy (PDT) and diagnostic assays for treatment assessment on a

210 to the progression of photodynamic therapy (PDT) and microbial photodynamic inactivation (PDI) in cl

211 on metal complexes for photodynamic therapy (PDT) and photoactivated chemotherapy (PACT), and discuss

212 y strategies including photodynamic therapy (PDT) and photothermal therapy (PTT) to treat many diseas

213 y enabling immunogenic photodynamic therapy (PDT) and promoting the maturation of dendritic cells (DC

214 The combination of photodynamic therapy (PDT) and radiation therapy (RT) more significantly inhib

215 o efficient probes for photodynamic therapy (PDT) and stochastic optical reconstruction microscopy (S

216 as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT).

217 hich is different from photodynamic therapy (PDT) by the use of highly penetrating acoustic waves to

218 Photodynamic therapy (PDT) can destroy local tumors and minimize normal tissue

219 Photodynamic therapy (PDT) efficacy is limited by the very short half-life and

220 it could be shown that photodynamic therapy (PDT) elevates antitumor immune responses.

221 chemotherapy drugs and photodynamic therapy (PDT) for ovarian cancer.

222 The utilization of photodynamic therapy (PDT) for the treatment of various types of cancer has ga

223 Photodynamic therapy (PDT) has been applied in cancer treatment by utilizing r

224 In recent years photodynamic therapy (PDT) has received widespread attention in cancer treatme

225 Photodynamic therapy (PDT) holds great promise for cancer therapy; however, it

226 The viable use of photodynamic therapy (PDT) in cancer therapy has never been fully realized bec

227 s and the discovery of photodynamic therapy (PDT) in the early 1900s, the landmark article in 1978 in

228 ous irradiation during photodynamic therapy (PDT) inevitably induces tumor hypoxia, thereby weakening

229 Photodynamic therapy (PDT) is a clinically approved anti-cancer treatment that

230 Photodynamic therapy (PDT) is a clinically approved therapeutic modality to tr

231 Photodynamic therapy (PDT) is a new strategy for treating local cancers using

232 Photodynamic therapy (PDT) is a promising cancer treatment modality that can s

233 Photodynamic therapy (PDT) is an approved modality for the treatment of variou

234 Photodynamic therapy (PDT) is an effective and cosmetically favorable treatmen

235 Photodynamic therapy (PDT) is an efficacious treatment for some types of cance

236 Photodynamic therapy (PDT) is an important cancer treatment modality due to it

237 Photodynamic therapy (PDT) is an important clinically relevant therapeutic mod

238 mors, oxygen-dependent photodynamic therapy (PDT) is considerably limited.

239 Photodynamic therapy (PDT) is widely used to treat diverse diseases, but its d

240 nophotosensitizers for photodynamic therapy (PDT) owing to their high photosensitizer loadings, facil

241 LAK)(2) conjugate as a photodynamic therapy (PDT) sensitizer.

242 tervention for cancer, photodynamic therapy (PDT) still suffers from limitations.

243 Although photodynamic therapy (PDT) takes advantage of the spatial-temporal control of

244 r photosensitizers for photodynamic therapy (PDT) through the enhanced penetration and retention effe

245 ided surgery (IGS) and photodynamic therapy (PDT) to resect and ablate cancer cells.

246 cells are subjected to photodynamic therapy (PDT) treatment in the presence of DPP, resulting in atte

247 t harnesses sub-lethal photodynamic therapy (PDT) using a photosensitiser that localises in endolysos

248 g combination standard photodynamic therapy (PDT) with intravitreal ranibizumab in the treatment of p

249 cence imaging (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and

250 Photodynamic therapy (PDT) with protoporphyrin IX (PpIX), which is endogenousl

251 Photodynamic therapy (PDT), a treatment that uses a photosensitizer, molecular

252 R in the no-treatment, photodynamic therapy (PDT), bevacizumab, and ranibizumab groups, respectively.

253 ly promising for smart photodynamic therapy (PDT), but achieving this goal remains a tremendous chall

254 t oxygen ((1)O(2)) for photodynamic therapy (PDT), but also triggers a spontaneous cascade reaction t

255 of porphyrin-mediated photodynamic therapy (PDT), including low depths of tissue penetration that re

256 nt tool (chemotherapy, photodynamic therapy (PDT), radiotherapy (RT)) by controlled drug delivery/rel

257 ote the development of photodynamic therapy (PDT), undesired side effects like low tumor specificity

258 ers by cancer cells in photodynamic therapy (PDT), we designed a smart plasma membrane-activatable po

259 which is exploited in photodynamic therapy (PDT).

260 totoxic therapy called photodynamic therapy (PDT).

261 rared (NIR) two-photon photodynamic therapy (PDT).

262 zumab; ranibizumab; or photodynamic therapy (PDT).

263 (PPIX) accumulation in photodynamic therapy (PDT).

264 of great interest for photodynamic therapy (PDT).

265 (2PLM) and two-photon photodynamic therapy (PDT).

266 ships for their use in photodynamic therapy (PDT).

267 ctive chemotherapy and photodynamic therapy (PDT).

268 desired for antitumor photodynamic therapy (PDT).

269 as photosensitizers in photodynamic therapy (PDT).

270 tal photochemistry and photodynamic therapy (PDT).

271 s, and sensitizers for photodynamic therapy (PDT); and more recently as models for aromaticity (both

272 ) and 7 investigating psychodynamic therapy (PDT).

273 n delivery to tumours, achieve deeper tissue PDT via red-shifted porphyrin Q-bands, energy transfer a

274 to provide current information pertaining to PDT use, including a discussion of in vitro and in vivo

275 mice bearing the same tumours 20min prior to PDT treatment.

276 ght eyes (5.9%) had complications related to PDT.

277 t difference in tumor hypoxia in response to PDT over time was found between the U87MG and MDA-MB-435

278 n overcoming the difficulty in transitioning PDT into the medical field.

279 o underwent verteporfin PDT using one of two PDT regimens at a tertiary referral centre in an Asian p

280 olyp closure and recurrences between the two PDT regimens.

281 Unfortunately, PDT is often followed by recurrence due to incomplete ab

282 rous tumours, treating hypoxic tumours using PDT can be a challenge.

283 asma/tumor ratio of the prodrug to achieve V-PDT (vascular targeted-PDT, 0.5 h), C-PDT (cellular targ

284 anaged in the pre-PDT (1967-2001) era versus PDT (2002-2018) era.

285 cular PCV patients who underwent verteporfin PDT using one of two PDT regimens at a tertiary referral

286 al features for tumor control (PDT alone vs. PDT plus additional therapy) revealed those controlled w

287 A comparison (pre-PDT [n = 220 cases] vs. PDT [n = 238 cases]) revealed PDT era patients were of o

288 Treatment (pre-PDT vs. PDT) included argon laser photocoagulation (42.1% vs. 0.

289 With PDT, Ce6-SCs demonstrate high singlet oxygen generation

290 IYIY-I2-BODIPY alone and in combination with PDT modulates the immune response in such a way that tum

291 onal therapy) revealed those controlled with PDT alone were more likely to be adenocarcinoma (73% vs.

292 pigmented posterior choroidal melanoma with PDT effectively preserves visual acuity, 5-year treatmen

293 EGF monotherapy and combination therapy with PDT yielded comparable outcomes as those of controlled c

294 s and 81 eyes with chronic CSCR treated with PDT and 64 untreated fellow eyes were evaluated.

295 cumscribed choroidal hemangioma treated with PDT were identified, and factors predictive of final vis

296 ribed choroidal hemangioma were treated with PDT.

297 MOLs (ca. 1.2 nm) enable highly effective X-PDT to afford superb anticancer efficacy.

298 X-ray-induced photodynamic therapy (X-PDT) combines both the advantages of radiotherapy (RT) a

299 ons in X-ray-induced photodynamic therapy (X-PDT) of colon cancer.

300 w-dose X-ray-induced photodynamic therapy (X-PDT) with negligible side effects.